Serum IL-33, a new marker predicting response to rituximab i
Background Recent works have suggested a possible link between interleukin (IL)-33 and B-cell biology. We aimed to study the possible association between serum IL-33 detection and response to rituximab (RTX) in rheumatoid arthritis (RA) patients in different cohorts with an accurate enzyme-linked immunosorbent assay (ELISA)....

http://arthritis-research.biomedcentral.com/articles/10.1186/s13075-016-1190-z
Like
Comment
Share